UNSPSC 51182077: Testosterone undecylate

This classification denotes a therapeutic testosterone with the molecular formula C30H48O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H16A5VCT9C, chemically known as 5-alpha-androstan-3-one, 17-beta-hydroxy-, undecanoate but more generally known as testosterone undecanoate, which bears US NIH Compound Identifier 65157. European Medicines Agency schedules Testosterone undecanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04744MIG.

Most nations, for tariff and trade purposes, schedule testosterone undecylate under HS 29372900. SMILES: CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.

UNSPSC 51182077 Testosterone undecylate is a Commodity code representing individual pharmaceutical active ingredients and formulations procured by state and local health systems, correctional facilities, and cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The scope encompasses manufacturer supply of pharmaceuticals with specified National Drug Codes, SKUs, UPCs, and packaging configurations, with vendors required to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. Solicitations under this code originate from multistate cooperative purchasing vehicles coordinating across state and local health systems rather than from individual jurisdictions or school districts; MMCAP functions as the primary issuing body for regional pharmaceutical procurement.

The code shows recent activity concentrated in the Upper Midwest and Pacific Northwest through the MMCAP cooperative vehicle serving Minnesota and Oregon. The RFP with response deadline March 26, 2026 represents the most recent documented opportunity; the contract term runs two years for new vendors with optional extensions, and awarded agreements become effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), with secondary weight on fixed pricing, administrative fee compliance, EDI capability, and pricing format flexibility. Vendors must carry commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million. The RFP reserves the right for sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, and does not identify explicit set-aside designations or disadvantaged-enterprise restrictions in available documentation.